The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multidisciplinary-guided digital solution to data capture in early-phase clinical trials.
 
Donna M. Graham
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Joanna Clarke
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Gemma Wickert
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merck Sharp & Dome (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
 
Leanna Goodwin
Research Funding - 3-V Biosciences (Inst); 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Actuate Therapeutics (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Athenex (Inst); Athenex (Inst); Bayer (Inst); Bayer (Inst); BerGenBio (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Carrick Pharm (Inst); Carrick Pharm (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Eisai (Inst); Genmab (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Ignyta (Inst); Incyte (Inst); Incyte (Inst); Janssen (Inst); Janssen (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Macrogenics (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck Sharp & Dome (Inst); Merck Sharp & Dome (Inst); Millenium Pharamceuticals (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Novartis (Inst); Octimet (Inst); Octimet (Inst); Orion (Inst); Orion (Inst); Redx Pharma (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Sierra Oncology (Inst); Synthon (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tarveda Therapeutics (Inst)
 
Carla Timmins
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merck Sharp & Dome (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
 
Dilshad Chang
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Genmab (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merck Sharp & Dome (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
 
Alison Walker
Research Funding - 3-V Biosciences (Inst); 3-V Biosciences (Inst); 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Actuate Therapeutics (Inst); Actuate Therapeutics (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Athenex (Inst); Athenex (Inst); Athenex (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BerGenBio (Inst); BerGenBio (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Carrick Therapeutics (Inst); Carrick Therapeutics (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Genmab (Inst); Genmab (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Ignyta (Inst); Ignyta (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck Sharp & Dome (Inst); Merck Sharp & Dome (Inst); Merck Sharp & Dome (Inst); Millenium Pharamceuticals (Inst); Millenium Pharamceuticals (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Octimet (Inst); Octimet (Inst); Octimet (Inst); Orion (Inst); Orion (Inst); Orion (Inst); Redx Pharma (Inst); Redx Pharma (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Sierra Oncology (Inst); Sierra Oncology (Inst); Synthon (Inst); Synthon (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tarveda Therapeutics (Inst); Tarveda Therapeutics (Inst)
 
Amanda Rees
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merck Sharp & Dome (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
 
Steffan Stringer
Employment - Foundry Health
 
Adam Theis
Employment - Foundry Health
 
Louise Carter
Consulting or Advisory Role - Athenex; Bicycle Therapeutics
Research Funding - Athenex (Inst); Bristol-Myers Squibb (Inst); Sierra Oncology (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Athenex; BerGenBio; BerGenBio
 
Natalie Cook
Consulting or Advisory Role - Epigene Therapeutics; Tarveda Therapeutics
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Redx Pharma (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst); Vertex (Inst)
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Janssen; Octimet; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio
 
Fiona Thistlethwaite
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Evelo Therapeutics; GlaxoSmithKline; Octimet (Inst)
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
Other Relationship - iMatch
 
Andrew M. Hughes
Leadership - PCI Biotech
Stock and Other Ownership Interests - AstraZeneca
Honoraria - AstraZeneca; Athenex; Athenex; Carrick Therapeutics; PCI Biotech; Roche/Genentech; Sarah Cannon Research Institute
Consulting or Advisory Role - As per item 4
Research Funding - AstraZeneca
 
Jennifer Bradford
Employment - Almac Diagnostics (I)
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca (Inst)